Clinical Trial Search

Primary: B Memory Cell Response (% of Memory B Cells That Are Antigen-specific) — 0.61; 0.94; 0.36; 0.08 % of memory B cells that are Ag-specific

Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement — 3.4; 79.9; 86.4…

Primary: Overall Survival — 56; 29 months

Primary: Change in Carotid Intima-media Thickness From Baseline to Year 1 — 0.766; 0.765; 0.758; 0.768 millmeter — p=0.7279

Primary: Percentage of Participants Who Experienced Freedom From MACE Within 30 Days Post-procedure — 93.8 percentage of participants

Primary: Change From Baseline in HbA1c at Week 26 — -0.22; -0.32; -0.46 percentage of HbA1c — p=0.2095

Primary: Change From Baseline In Hemoglobin At Week 24 — 7.94; 10.33; 2.39 g/dL

Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months

Primary: Number of Participants Reported Adverse Events (AEs), Serious Adverse Events (SAEs) — 6; 6; 0; 0 Participants

Primary: Number of Participants With Clinical Remission at Different Time Points of Assessment — 12; 8; 10; 13 Participants — p=0.42

Primary: Change in Cardiac Iron Content From Baseline to Month 12 — 1.09 ratio

Primary: Overall Response Rate — 1; 1; 3; 1 Participants

Primary: Pregnancy Rate — 99; 71; 24; 4 Participants

Primary: Daily Step Count — 1409; -149 Steps

Primary: Pain Intensity at Rest Evaluated Using a 0-100 mm VAS — 9.6; 16.9; 18.4; 8.1 score on a scale